First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Letter Hematology

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine

Omar Tarawneh et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Letter Hematology

Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine

Sudhamshi Toom et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Editorial Material Hematology

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Eun-Ju Lee et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Hematology

Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP

Alexandra Schifferli et al.

Summary: Diagnosis of secondary ITP or non-IT in children requires consideration of individual case details and underlying causes, with younger ages typically associated with infectious or autoimmune diseases, while malignancies and aplastic anemia should be considered in older patients.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Hematology

Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience

Tariq Kewan et al.

Summary: COVID-19-induced ITP typically presents after the first week of symptoms beginning, with most patients having WHO Grade 1-2 bleeding scores. Standard treatment with glucocorticoids and IVIG is effective in achieving an excellent response in most cases, but the safety of eltrombopag in COVID-19 patients needs further research for better safety profile.

TRANSFUSION (2021)

添加到收藏夹

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal et al.

Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Editorial Material Infectious Diseases